HOME ABOUT US PRINT PUBLICATIONS SUBSCRIPTIONS CONTACT US RSS
 
Subscriber Sign In
 
Today@FDA
FDA Calendar
 
Archived Daily Updates
 
FDA Whistleblower
 
What do you think?
Search our 63,616-story database
Search
Renew subscription










E-mail This to a Friend | Print Format  
     
 
PMRS Sues FDA Over Hearing on Rejected NDA
09/14/2018
 

Pharmaceutical Manufacturing Research Services (PMRS) has filed a lawsuit against FDA in eastern PA federal court seeking an order to compel the agency to provide a hearing on its decision not to approve the company’s NDA for oxycodone hydrochloride immediate-release oral capsules (see earlier story). In the complaint, PMRS argues that it provided sufficient data, information and analyses that would legally entitle it for a hearing on the NDA rejection.


On 11/16/2017, CDER issued a complete response letter to PMRS and described the specific deficiencies. They included issues with the proposed labeling describing abuse-deterrent properties, and the safety and purity of the excipients intended (but not shown) to confer abuse deterrent properties were not adequately characterized. Additionally, the letter described additional deficiencies related to chemistry, manufacturing, and controls and current good manufacturing practice requirements.


Post an instant comment on this report here

 
Any copying or electronic transfer without written permission is strictly prohibited and will result
in termination of service and prosecution under the federal Copyright Act.
To gain permission to copy this article log on to http://www.copyright.com.

FERDIC INCORPORATED - P.O. Box 28, Camp Hill, PA 17001 | Phone: (717)731-1426 fax:(717)731-1427 Email: info@fdaweb.com